



Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 09/11/2021

Ref: 21-22 360

Freedom of Information request

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 15/10/2021. Please see responses to your requests below.

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- **Avelumab + Axitinib**
- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Lenvantinib + Everolimus**
- **Nivolumab**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab + Axitinib**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other**

The Trust is only able to provide information in relation to drug dispensing, we do not record diagnoses on our clinical systems so therefore we are unable to link the type of drug to diagnosis.

To extract this information, we would have to search through a significant amount of patient records. It is estimated that to attempt to retrieve all the information you require would take a considerable amount of retrieval time, which would exceed 18 hours. This would exceed the appropriate limit for dealing with a Freedom of Information Request, in terms of costs and therefore Section 12(1) of the Freedom of Information Act 2000 applies

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib AND Trametinib**

- Encorafenib AND Binimetinib
- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

Please see answer in question 1.

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- Cobimetinib
- Dabrafenib
- Dabrafenib AND Trametinib
- Encorafenib AND Binimetinib
- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

Please see answer in question 1.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Code	Primary Procedure Desc	Jul- Sept 2021
M02.1	NEPHRECTOMY AND EXCISION OF PERIRENAL TISSUE	7
M02.2	NEPHROURETERECTOMY NEC	2
M02.3	BILATERAL NEPHRECTOMY	1
M02.5	NEPHRECTOMY NEC	19
M03.9	UNSPECIFIED	1
M03.9	UNSPECIFIED PARTIAL EXCISION OF KIDNEY	6
Total:		36

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team